Publications in collaboration with researchers from Columbia University Medical Center (3)

2025

  1. Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A

    Journal of Thoracic Oncology, Vol. 20, Núm. 5, pp. 651-664

2019

  1. Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients

    Clinical Lung Cancer, Vol. 20, Núm. 6, pp. e601-e608

2018

  1. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

    The Lancet Oncology, Vol. 19, Núm. 4, pp. 521-536